TRUE Private Wealth Advisors purchased a new stake in shares of Zoetis Inc (NYSE:ZTS) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,211 shares of the company’s stock, valued at approximately $202,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Sun Life Financial INC increased its stake in shares of Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after purchasing an additional 1,124 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after buying an additional 1,365 shares in the last quarter. Fort L.P. purchased a new stake in Zoetis in the 2nd quarter worth $121,000. Private Capital Group LLC increased its stake in Zoetis by 118.4% in the 1st quarter. Private Capital Group LLC now owns 1,529 shares of the company’s stock worth $128,000 after buying an additional 829 shares in the last quarter. Finally, Lenox Wealth Advisors LLC increased its stake in Zoetis by 259.4% in the 2nd quarter. Lenox Wealth Advisors LLC now owns 1,682 shares of the company’s stock worth $143,000 after buying an additional 1,214 shares in the last quarter. 89.75% of the stock is currently owned by hedge funds and other institutional investors.
In other Zoetis news, insider Roman Trawicki sold 8,266 shares of Zoetis stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $92.53, for a total value of $764,852.98. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, October 1st. The stock was sold at an average price of $92.03, for a total transaction of $184,060.00. The disclosure for this sale can be found here. Insiders sold 208,467 shares of company stock worth $19,071,625 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.
Shares of NYSE:ZTS opened at $92.77 on Friday. The company has a market cap of $44.70 billion, a PE ratio of 38.65, a P/E/G ratio of 1.78 and a beta of 0.97. Zoetis Inc has a one year low of $67.44 and a one year high of $96.57. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.06. The company had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.46 billion. Zoetis had a net margin of 20.35% and a return on equity of 77.52%. Zoetis’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $0.65 earnings per share. Sell-side analysts anticipate that Zoetis Inc will post 3.1 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.54%. The ex-dividend date is Monday, November 19th. Zoetis’s dividend payout ratio is currently 20.83%.
A number of brokerages have issued reports on ZTS. Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Friday, July 27th. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 price target on shares of Zoetis in a research note on Thursday, August 2nd. Stifel Nicolaus raised their price objective on Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Bank of America raised their price objective on Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Finally, Morgan Stanley raised their price objective on Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average target price of $93.19.
Zoetis Company Profile
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Featured Article: Fiduciary
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.